Results 51 to 60 of about 17,756 (301)
Long term outcome after coronary stent implantation: a 10 year single centre experience of 1000 patients [PDF]
, 1999 OBJECTIVE: To describe the long term clinical outcome (up to 11 years) after coronary stenting. DESIGN: A single centre observational study encompassing 1000 consecutive patients with a first stent implantation (1560 stents) between ...
Brand, M.J.B.M. (Marcel) van den +7 more
core +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang +6 more
wiley +1 more source
PLoS ONE, 2019 Background and purposeThe ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008.
Han-Gil Jeong +3 more
doaj +1 more source
Journal of Mass Spectrometry, 2013 Ticlopidine, an antiplatelet drug, undergoes extensive oxidative metabolism to form S-oxide, N-oxide, hydroxylated and dealkylated metabolites. However, metabolism of ticlopidine via conjugation has not been thoroughly investigated.
Fuying Du, Q. Ruan, M. Zhu, J. Xing
semanticscholar +1 more source
Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis
Canadian Journal of Gastroenterology, 1996 Ticlopidine hydrochloride has been shown to reduce the risk of first or recurrent stroke in patients who have experienced a transient ischemic attack, reversible ischemic neurological deficit, recurrent stroke or first stroke. Severe liver dysfunction is
Sander Jo Veldhuyzen van Zanten +1 more
doaj +1 more source
Antiaggregant therapy in neurological practice: objectives and possibilities
Неврология, нейропсихиатрия, психосоматика, 2010 Based on the data available in the literature, the authors consider the prevention of ischemic stroke and other cardiovascular diseases in high-risk group patients.
E. V. Portnyagina, A. F. Portnyagin
doaj +1 more source
Warfarin interactions: a letter to editor [PDF]
Patient Safety and Quality Improvement Journal, 2019 Today, with the advances in the treatment of cardiovascular patients such as intravascular stents, cardiac valves and intraventricular pacing and heart transplantation, many patients require the use of anticoagulants such as warfarin, sprain, Plavix ...
Sayyed Majid Sadrzadeh +4 more
doaj +1 more source
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion [PDF]
, 2017 The effects of the antiaggregant substance ticlopidine and of the anticoagulant acenocoumarol on patency rates of aorto-coronary bypass grafts were compared in a prospective randomized trial. Ticlopidine, 250 mg b.i.d.
GOEBEL, N. +7 more
core
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. [PDF]
, 2015 BACKGROUND: Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths.
A Kumar +19 more
core +3 more sources
Ticagrelor: A Reversible P2Y12 Inhibitor in Preventionof Thrombotic Events
RUHS Journal of Health Sciences, 2023 Antiplatelet drugs play a crucial role in patients of coronary artery diseases, cerebrovascular diseases, and maintaining the patency of revascularised arteries and stents after coronary angioplasty.
Uma Advani , Charu Jain , Alka Bansal , Neha Sharma , Kopal Sharma
doaj +1 more source